RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Chang-Wei-Qing Combined with PD-1 Inhibitor Alleviates Colitis-Associated Colorectal Tumorigenesis by Modulating the Gut Microbiota and Restoring Intestinal Barrier.
Chang-Wei-Qing Combined with PD-1 Inhibitor Alleviates Colitis-Associated Colorectal Tumorigenesis by Modulating the Gut Microbiota and Restoring Intestinal Barrier.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肠复方(CWQ)是一种广泛认可的中药复方,由黄芪、党参、白术、茯苓、薏苡仁、三叶木通、红藤和毛葡萄组成。该复方因在缓解结直肠癌方面的积极作用而受到广泛关注,当其与 PD-1 联合使用时,会影响一些与TIL(肿瘤浸润淋巴细胞)相关的肠道菌群。
然而,CWQ 联合 PD-1 抑制剂抑制 AOM/DSS 处理小鼠中结肠炎相关结直肠癌(CAC)的生物学依据仍有待探索。
我们的目的是探讨 CWQ 联合 PD-1 抑制剂对 CAC 的化学预防作用,重点关注其对肠道菌群的调节。采用氧化偶氮甲烷(AOM)和葡聚糖硫酸钠(DSS)处理建立 CAC 小鼠模型。组织样本的病理学评估包括免疫组织化学和苏木精-伊红染色。通过透射电子显微镜评估肠道屏障功能。分别通过 16 S rRNA 基因测序和液相色谱-质谱联用分析粪便菌群和代谢物。接受抗生素处理的小鼠作为粪便菌群移植模型。CWQ 联合 PD-1 抑制剂可抑制 AOM/DSS 处理小鼠的 CAC。该联合治疗通过增加微生物多样性、富集 Limosilactobacillus 和 Bifidobacterium 等益生菌群,以及减少 Desulfovibrio 等致病菌,有效缓解了 CAC 模型中的肠道菌群失调。
此外,CWQ 联合 PD-1 抑制剂下调了与 NF-kappa B 信号通路相关的代谢物。联合治疗还显著改善了CAC小鼠的肠道屏障功能。透射电子显微镜显示,CWQ联合PD-1抑制剂组细胞完整性增强,线粒体结构相对正常且膜完整,内质网更丰富且未扩张,突显了该联合方案对肠道屏障完整性的保护作用。转录组分析进一步表明,联合治疗上调了参与紧密连接和黏附连接的基因,同时下调了与先天免疫应答相关的基因。CWQ联合PD-1抑制剂可改善AOM/DSS小鼠模型中的菌群失调,肠道微生物组的代谢产物可能具有抗炎活性。
此外,CWQ联合PD-1抑制剂改善肠道屏障功能,从而有效抑制CAC的发生和发展。
Chang-Wei-Qing (CWQ) is a widely recognized Traditional Chinese Medicine (TCM) formulation composed of Astragalus, Codonopsis, Atractylodes, Poria, Coix seed, Akebia trifoliata Koidz, Sargentodoxa cuneata, and Vitis quinquangularis Rehd. This formulation has garnered significant interest for its positive effects in mitigating colorectal cancer, and when combined with PD-1, it affects some gut microbiota associated with tumor infiltrating lymphocytes cells.
However, the biological rationale underlying the suppression of colitis-associated colorectal cancer (CAC) in AOM/DSS-treated mice by CWQ combined with PD-1 inhibitor remains to be explored.
Our aim is to explore the chemopreventive effect of CWQ combined with PD-1 inhibitor on CAC, with a focus on modulating the gut microbiota. A mouse model of CAC was established using azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment. Pathological evaluation of tissue samples included immunohistochemistry and hematoxylin and eosin staining. Intestinal barrier function was assessed by transmission electron microscopy.
Fecal microbiota and metabolites were analyzed through 16 S rRNA gene sequencing and liquid chromatography-mass spectrometry, respectively. Mice treated with antibiotics served as models for fecal microbiota transplantation. CWQ combined with PD-1 inhibitor suppressed CAC in AOM/DSS-treated mice. This combined therapy effectively alleviated gut dysbiosis in the CAC model by increasing microbial diversity, enriching probiotic populations such as Limosilactobacillus and Bifidobacterium, and reducing pathogenic bacteria like Desulfovibrio.
Additionally, CWQ combined with PD-1 inhibitor downregulated metabolites associated with the NF-kappa B signaling pathway. The combined treatment also significantly improved intestinal barrier function in CAC mice. Transmission electron microscopy of the CWQ combined with PD-1 inhibitor group showed enhanced cellular integrity, a relatively normal mitochondrial structure with intact membranes, and a more abundant, unexpanded endoplasmic reticulum, underscoring the protective effects of this combination on intestinal barrier integrity.
Transcriptomic analysis further demonstrated that the combined therapy upregulated genes involved in tight and adherens junctions, while downregulating genes linked to innate immune responses. CWQ combined with PD-1 inhibitor can ameliorate dysbiosis in the AOM/DSS mouse model, with the metabolites of the gut microbiome potentially possessing anti-inflammatory activity.
Moreover, CWQ combined with PD-1 inhibitor improves intestinal barrier function, thereby effectively inhibiting the occurrence and development of CAC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。